Overview

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.

Phase:

Phase 1

Details

Lead Sponsor:

RTOG Foundation, Inc.

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Cetuximab
Cisplatin
Nivolumab